Premium
Role of gut microbiota in the immunopathology of atherosclerosis: Focus on immune cells
Author(s) -
Wang Chong,
Deng Hualing,
Liu Fang,
Yin Qing,
Xia Lin
Publication year - 2022
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/sji.13174
Subject(s) - immune system , gut flora , biology , immunology , lipopolysaccharide , peptidoglycan , innate immune system , microbiology and biotechnology , bacteria , genetics
Gut microbiota (GM) plays important roles in multiple organ function, homeostasis and several diseases. More recently, increasing evidences have suggested that the compositional and functional alterations of GM play a crucial role in the accumulation of foam cells and the formation of atherosclerotic plaque in atherosclerosis. In particular, the effects of bacterial components and metabolites on innate and adaptive immune cells have been explored as the underlying mechanisms. Understanding the effects of GM and metabolites on immunoregulation is important for clinical therapy for atherosclerosis. Herein, we summarize the potential role of the GM (such as bacterial components lipopolysaccharide and peptidoglycan) and GM‐derived metabolites (such as short‐chain fatty acids, trimethylamine N‐oxide and bile acids) in the immunopathology of atherosclerosis. Based on that, we further discuss the anti‐atherosclerotic effects of GM‐directed dietary bioactive factors such as dietary fibres, dietary polyphenols and probiotics. Because of drug‐induced adverse events in anti‐inflammatory therapies, personalized dietary interventions would be potential therapies for atherosclerosis, and the interactions between GM‐derived products and immune cells should be studied further.